Literature DB >> 21241803

Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships.

Aurélie Prémaud1, Annick Rousseau, Gyasi Johnson, Cindy Canivet, Peggy Gandia, Fabrice Muscari, Jean Marie Peron, Lionel Rostaing, Pierre Marquet, Nassim Kamar.   

Abstract

Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 α-chain (CD25) and transferin receptor (CD71) expression. The aim of this study was to confirm, quantify and model these PK/PD relationships. Full profiles of MPA plasma concentrations, T-cell proliferation, intracytoplasmic IL-2 and TNF-α expression, and both CD71 and CD25 expression were collected over the 12h after dosing in 10 patients on the waiting list for liver transplantation. Data were analyzed using NONMEM(®). Both CD25 and CD71 expression and T cell proliferation clearly decreased (median of decrease from baseline 62%, 68% and 94%, respectively) with increasing MPA concentrations, in contrast to IL-2 and TNF-α expression. The CD25 and CD71 baseline expression (E(0)) and maximum effect (E(max)) were correlated with the E(0) and E(max) values of T-cell proliferation (r(2)=0.509 and r(2)=0.622, respectively). The CD25, CD71 expression and T-cell proliferation profiles were adequately fitted using a sigmoid inhibitory E(max) model. Low estimated values (≤2 mg/L) for 50% inhibitory MPA concentrations were obtained. This study confirmed a transient MPA concentration-dependent decrease in T-cells expressing CD25 and CD71 and a strong reduction of T-cell proliferation and showed that CD25 and CD71 expression was correlated with T-cell proliferation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241803     DOI: 10.1016/j.phrs.2011.01.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds.

Authors:  M Grobman; D M Boothe; H Rindt; B G Williamson; M L Katz; J R Coates; C R Reinero
Journal:  J Vet Pharmacol Ther       Date:  2017-06-25       Impact factor: 1.786

2.  Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.

Authors:  Min Dong; Tsuyoshi Fukuda; Shareen Cox; Marij T de Vries; David K Hooper; Jens Goebel; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

3.  Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs.

Authors:  Michael Klotsman; Sebastien Coquery; Gayatri Sathyan; Vatsala Naageshwaran; Paddy Shivanand; Amanda J Fairchild; Oliver A Garden; Wayne H Anderson
Journal:  Front Vet Sci       Date:  2021-01-28

4.  In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes.

Authors:  Maciej Guzera; Lidia Szulc-Dąbrowska; Anna Cywińska; Joy Archer; Anna Winnicka
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

5.  Additive reductions in zebrafish PRPS1 activity result in a spectrum of deficiencies modeling several human PRPS1-associated diseases.

Authors:  Wuhong Pei; Lisha Xu; Gaurav K Varshney; Blake Carrington; Kevin Bishop; MaryPat Jones; Sunny C Huang; Jennifer Idol; Pamela R Pretorius; Alisha Beirl; Lisa A Schimmenti; Katie S Kindt; Raman Sood; Shawn M Burgess
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

6.  CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients.

Authors:  Leila Amini; Dimitrios Laurin Wagner; Uta Rössler; Ghazaleh Zarrinrad; Livia Felicitas Wagner; Tino Vollmer; Désirée Jacqueline Wendering; Uwe Kornak; Hans-Dieter Volk; Petra Reinke; Michael Schmueck-Henneresse
Journal:  Mol Ther       Date:  2020-09-08       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.